Podcasts about kansas university medical center

Could the key to more effective allergy therapies lie in the nasal microbiome? In this episode of BackTable ENT, Dr. Jennifer Villwock from Kansas University Medical Center discusses the intricacies of treating allergies and sinus issues with hosts Dr. Ashley Agan and Dr. Gopi Shah. --- SYNPOSIS Dr. Villwock begins by highlighting the importance of personalized medicine and the role of the microbiome in immunotherapy. Topics include topical and oral probiotics, the nasal microbiome, intralymphatic immunotherapy, and the significance of accurate allergy testing. Dr. Villwock also shares insights on sublingual and subcutaneous immunotherapy, the future of allergy treatments, and the impact of environmental factors on sinus health. --- TIMESTAMPS 00:00 - Introduction 01:53 - Understanding the Sinus Microbiome 04:34 - The Role of the Microbiome in Health 09:31 - Challenges in Microbiome Research 23:21 - Clinical Decision-Making in Antibiotic Use 25:07 - Exploring Probiotics & Dietary Factors for Sinus Health 30:12 - Immunotherapy and Microbiome 35:47 - Allergy Testing Methods 41:40 - Future Directions in Immunotherapy 44:18 - Conclusion and Final Thoughts --- RESOURCES Jennifer Villwock Profile https://www.kumc.edu/jvillwock.html AAOA 2025 Explorers Course in Allergy and Immunology, Vail, CO. March 27-29, 2025 https://www.aaoallergy.org/education/aaoa-explorers-course-2025/ BackTable+ for ENT https://plus.backtable.com/pages/ent Check out BackTable+ for ENT, our sponsor and new e-learning platform! https://plus.backtable.com/pages/ent

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) recently-appointed vice president of sales Alan Huang spoke with Proactive's Stephen Gunnion about his role and Polarean's sales growth strategy. Appointed in September, Huang brings over a decade of experience in medtech imaging, previously serving as general manager for Philips MRI in North America. Discussing his decision to join Polarean, Huang expressed admiration for Polarean's innovative lung imaging technology, noting, “I was also really impressed with Polarean's innovative functional lung imaging technology and the significant clinical challenges that it addresses.” In his role, Huang's primary focus is on increasing global revenue, beginning with the US market, where the company has FDA approval and favourable reimbursement conditions. He outlined a three-pronged sales strategy: enhancing utilisation at current customer sites, targeting new system sales to high-potential healthcare facilities, and expanding relationships with major MRI manufacturers. Notably, Polarean has strategic partnerships with Philips, General Electric, and Siemens, positioning the company to increase its presence in radiology departments across the US. Huang highlighted recent successes, including upgrades at Kansas University Medical Center and the University of Virginia, while projects are underway at Duke University and the University of Iowa. Watch the full interview for insight into Polarean's growth plans in functional lung imaging technology. For more in-depth discussions, visit Proactive's YouTube channel, and don't forget to like, subscribe, and enable notifications for future content. #PolareanImaging #LungImaging #MedicalTechnology #AlanHuang #SalesStrategy #HealthcareInnovation #MRITechnology #ProactiveInvestors #Radiology #FunctionalImaging#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Interviewees: Raffi Najarian and Justin Ramsey Interviewer: Lisa Meeks Description: In this conversation, Lisa Meeks interviews Raffi Najarian and Justin Ramsey, both pediatric rehabilitation physicians with cerebral palsy. They discuss their journey to medical school and the challenges they faced along the way. Raffi shares his experience of applying to medical school and the support he received from his family. Justin talks about the internal barriers he faced and the importance of finding the right mentor. They also discuss the challenges they encountered during medical school, including access barriers. In this conversation, Raffi Najarian and Justin Ramsey discuss their experiences as medical students with disabilities. They share the challenges they faced in anatomy lab and how they overcame them. They also talk about dealing with difficult faculty members and the importance of kindness and feedback in medical training. Raffi and Justin explain why they chose physiatry as their specialty and the impact they have on their patients. They emphasize the importance of visibility and representation for individuals with disabilities in the medical field. Finally, they offer advice for students with disabilities who are considering a career in medicine. Keywords: physiatry, medical education, doctors with disabilities, cerebral palsy, pediatric rehabilitation, med school applications, accessibility, accommodations, disability representation Transcript: https://bit.ly/3yuxJf8 Bios: Justin Ramsey, M.D. is board certified in Physical Medicine and Rehabilitation and is sub-specialty boarded in Pediatric Rehabilitation Medicine. He graduated from the Kansas University School of Medicine. He then completed his Physical Medicine and Rehabilitation training at the Kansas University Medical Center and a fellowship program in Pediatric Rehabilitation Medicine at Children's Mercy Hospital (Kansas City, MO). Dr. Ramsey spent several years as faculty with the Pediatric Rehabilitation Medicine fellowship program at Children's Mercy Hospital and the Kansas University Medical Center's Physical Medicine and Rehabilitation Department. He has served as chair of the Advocacy Committee for the American Academy for Cerebral Palsy and Developmental Medicine and has served on its Communications Committee. Currently, he works at a private pediatric rehabilitation hospital (Bethany Children's Health Center) near Oklahoma City, which specializes in the care of children with disabilities. In collaboration with neurology and OU Health Science Center's neurosurgery department, he has created Oklahoma's joint pediatric movement clinic. He currently serves as the Associate Medical Director for the Movement clinic and Cerebral Palsy. He volunteers as a Clinical Associate Professor of Neurology at The University of Oklahoma Health Sciences Center. Justin has hemiparetic cerebral palsy and is active in local advocacy. He is married to his wife (Kendra) and has 2 beautiful young children (Ryan and Reese), who keep his family busy. Medical and disability education are some of his major subjects of interest. He is grateful for early college experiences in working with individuals with disabilities while volunteering at Hetlinger Developmental Services, Inc in his hometown of Emporia, KS. Dr. Raffi Najarian has been in practice since 2013. He is a pediatric physiatrist and director of the Spasticity Clinic at Akron Children's Hospital. A graduate of the University of Michigan and Wayne State University School of Medicine in Detroit, MI, he completed his residency in physical medicine and rehabilitation at MetroHealth Rehabilitation Institute of Ohio in Cleveland. He then completed a fellowship in Pediatric Rehabilitation Medicine at Gillette Children's Specialty Healthcare in Saint Paul, MN. Dr. Najarian has a special interest in cerebral palsy, spasticity management, brain injury, stroke, spinal cord injury, spina bifida, acute inpatient and outpatient rehabilitation and concussion management. He is certified by the American Board of Physical Medicine and Rehabilitation and subspecialty certified in Pediatric Rehabilitation Medicine. He is a member of the American Academy of Physical Medicine and Rehabilitation and the American Academy for Cerebral Palsy and Developmental Medicine, and served on the latter's Lifespan Committee.  He is an Associate Professor of Pediatrics at Northeast Ohio Medical University (NEOMED).  Raffi has diplegic cerebral palsy and is an advocate for children and adults with disabilities.  He serves as a member of the United Cerebral Palsy Research Committee and on the board of directors for Adaptive Sports Ohio, while participating  as an active member of the Akron Rhinos wheelchair rugby team.   Produced by: Gabe Abrams and Dr. Lisa Meeks.  Audio editor: Jacob Feeman Digital Media: Katie Sullivan Resources: Professional Learning Series - United Cerebral Palsy, UCP Research Initiative & Committee - United Cerebral Palsy, Physicians' Perceptions Of People With Disability And Their Health Care   https://www.yourcpf.org https://cprn.org  

In this episode of The Healers Café, Manon Bolliger (facilitator and retired naturopath with 30+ years of practice) with Sylvie Beljanski about nonprofit, whose working towards curing cancer the natural way For the transcript and full story go to: https://www.drmanonbolliger.com/sylvie-beljanski     Highlights from today's episode include: Sylvie Beljanski 14:49 I think we have to be relentless. We have to keep speaking. Keep publishing, keep being there for all the people who want to learn about their own health and take it as they want to learn about how to take care of themselves, what is available to them naturally. Sylvie Beljanski So here we have a natural product which is going to help preserve bone marrow to do its own work without toxicity and therefore it means all the families of white blood cells are going to be created without any imbalance without growth factor and so on. Sylvie Beljanski So, when you have something that really really works, it finds its way one way or another. It is at some point recognized and therefore, never give up because it will eventually be recognized by good people with an open mind that will recognize the value of the science and give it a chance.   ABOUT SYLVIE BELJANSKI: Sylvie Beljanski, a French lawyer by trade, is a health advocate for holistic medicine, public speaker, internationally known author and entrepreneur. She is the Founder and Executive Vice President of The Beljanski Foundation, whose mission is to research natural approaches to cancer. She is also the CEO of Maison Beljanski, an international dietary supplement company. Ms. Beljanski is the award winning author of "Winning The War On Cancer: The Epic Journey Towards a Natural Cure". This book has helped propel Ms. Beljanski to be a sought-after speaker at health and wellness conferences globally, where she has educated thousands of people about scientific breakthroughs in the field of integrative medicine. Core purpose/passion: The Beljanski Foundation's mission is to sponsor research programs with various natural extracts recognized by Dr. Mirko Beljanski for their anticancer properties. Research has entailed programs on prostate cancer at Columbia University, including advanced prostate cancer that no longer responds to chemotherapy, as well as ovarian and pancreatic cancers at Kansas University Medical Center. All of these studies were completed using the same botanical extracts. They have been reported to be effective on both males and females and have also exhibited great synergy with a variety of chemotherapies. Research studies have proven that these same extracts are also effective against cancer stem cells, those cells deemed to be responsible for cancer relapse and metastasis. Passionate does not do justice for how driven I am to share the message about the effects and possibility for the extracts to save people's lives. Cancer researchers are all pursuing different goals. Some want to have something approved by the FDA, some want to milk an old patent into a new one and provide a new life to an old, ineffective molecule, and some simply want to cure people. All of these goals are very different and it is difficult to imagine that they could work together. However, since a number of prestigious universities have published their results with several Beljanski extracts, I have seen increased interest from researchers at other institutions and I would love to see The Beljanski Foundation establish new partnerships across the board. There is still so much research to be done. Website | Facebook  |  Instagram | YouTube | LinkedIn | Twitter | WinningTheWarOnCancer.com   ABOUT MANON BOLLIGER As a recently De-Registered board-certified naturopathic physician & in practice since 1992, I've seen an average of 150 patients per week and have helped people ranging from rural farmers in Nova Scotia to stressed out CEOs in Toronto to tri-athletes here in Vancouver. My resolve to educate, empower and engage people to take charge of their own health is evident in my best-selling books:  'What Patients Don't Say if Doctors Don't Ask: The Mindful Patient-Doctor Relationship' and 'A Healer in Every Household: Simple Solutions for Stress'.  I also teach BowenFirst™ Therapy through Bowen College and hold transformational workshops to achieve these goals. So, when I share with you that LISTENING to Your body is a game changer in the healing process, I am speaking from expertise and direct experience". Mission: A Healer in Every Household! For more great information to go to her weekly blog:  http://bowencollege.com/blog.    For tips on health & healing go to: https://www.drmanonbolliger.com/tips   ABOUT THE HEALERS CAFÉ: Manon's show is the #1 show for medical practitioners and holistic healers to have heart to heart conversations about their day to day lives. Follow on Social – Facebook | Instagram | LinkedIn | YouTube | Twitter | Linktr.ee | Rumble   * De-Registered, revoked & retired naturopathic physician after 30 years of practice in healthcare. Now resourceful & resolved to share with you all the tools to take care of your health & vitality!   Remember to subscribe if you like our videos. Click the bell if you want to be one of the first people notified of a new release.  

This edition of the Life of Fitz podcast features host Tim Fitzgerald calling his friend Marty Miller, brother of former Kansas State quarterback and assistant coach, Matt Miller. On January 8, 2022, Matthew Lee Miller died peacefully at the age of 49 at the Kansas University Medical Center in Kansas City, Kansas, after an 18-month battle against prostate cancer. Matt Miller was a guest on last season's Life of Fitz, during which he shared his message about men's health and making sure men 45 and older regularly ask their doctor to check their PSA score, the strongest indicator of problems with the prostate. As you may know, Fitz also has stage four prostate cancer, but he was declared in remission last December after more than four years of treatment and monitoring. Les Miller, the father of Marty and Matt, died on January 5 shortly before Matt's passing last holiday season. Les Miller was a longtime player personnel director in the NFL, including stints with the Kansas City Chiefs and San Diego Chargers. Marty Miller has been a West Coast scout with the Jacksonville Jaguars for nearly 20 years, working out of Boise, Idaho. *** Tim Fitzgerald is a sports journalist who writes, does TV, radio and is a long-time podcaster. He has served as publisher of GoPowercat.com, a website that focuses on Kansas State sports, for nearly 25 years. Fitz also has stage four prostate cancer, so during the initial stages of the pandemic, his doctors have advised him to stay home and lay low. Now, Fitz is healthy and in remission, but his podcast lives on. Welcome to his life and the Life of Fitz podcast. Sign up for GoPowercat VIP access and get your first month for just $1! Want the latest Kansas State headlines sent to your inbox? Click to sign up for GoPowercat's daily newsletter!  Make sure you subscribe to Life of Fitz at your favorite podcast provider, including Apple, Spotify or Amazon. Follow @LifeofFitz Learn more about your ad choices. Visit megaphone.fm/adchoices

Co-hosts Catherine and Francis were joined by Liz Toland, RDN (bio below), at Ellwood Thompson's grocer in Richmond, Virginia for a live podcast! Acting as emcee, Catherine facilitated a poignant discussion about eating disorder treatment, recovery, body image, nutrition, and finding space to heal. The audience was able to interact and ask questions (unfortunately the internet wasn't on our side and we missed most of those questions!), and Catherine, Francis, and Liz were able to interact and respond directly with folx. It was a room full of energy and vulnerability, and an evening of important discussion. We were so thankful for Liz's participation, and for all those who were present to listen, learn, provide their insights and ask questions. Liz Toland Bio: Liz is a graduate of Virginia Tech and holds degrees in Psychology and Human Nutrition, Foods, and Exercise. She completed the VCU Health System Dietetic Internship where she specialized in Clinical Nutrition and completed rotations at an eating disorder treatment center. Liz later worked at this same facility, specializing in the treatment of eating disorders. Liz's passion for nutrition counseling began during her undergraduate studies when she counseled individuals as part of her dietetic course work. Liz's food philosophy is that all foods fit into a balanced lifestyle, and finding the right path to health is unique for each individual. She aims to help clients achieve balance through intuitive eating and eating competence principles.Liz received her Masters of Science in Dietetics from Kansas University Medical Center and is a Registered Dietitian Nutritionist (RDN). Liz is a member of the Academy of Nutrition and Dietetics, the International Federation of Eating Disorder Dietitians, and the International Association for Eating Disorder Professionals (IAEDP). Liz sees clients in the Richmond, VA office.

Today we talk with Dr. Manni Mohyuddin of Kansas University Medical Center on his new paper out now in JAMA Network Open titled "Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review". Postprotocol Therapies: doi.org/10.1001/jamanetworkopen.2021.8084 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Today we interview Dr. Ghulam Rehman Mohyuddin of Kansas University Medical Center on his new paper out now in The Lancet Haematology titled "Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review". Control Groups: doi.org/10.1016/S2352-3026(21)00024-7 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Sabrina has been in healthcare for over 20 years. She attended Kansas University Medical Center and worked as a RN in the intensive care unit, pre-surgery and post surgery departments. She has worked in hospitals, outpatient surgery centers and clinics. After seeing patients continue to get more sick over the years, she decided she needed to be in a preventative role and she became a Family Nurse Practitioner graduating from Regis University Summa Cum Laude. She intuitively knew just prescribing medications to treat symptoms was not the answer and has taken many classes, including all the Institute of Functional Medicine classes. She attends many workshops and conferences including the International Society of Environmentally Acquired Illness, or ISEAI, to look for "root causes" of symptoms. She uses a Functional Medicine approach using Evidenced Based Medicine to help understand why you feel the way you do, and reverse the cause of your illness using pharmaceuticals and/or herbal medicine and advanced testing. Her understanding of the body, mind and spirit with her certification as a Family Nurse Practitioner, Reiki therapist and Certified Massage Therapist, can help bring you back to your True Self. It is truly her life passion to help each patient individually be the best they can be!

Join Dr. Holmes as she interviews Isleen Giminez Morales, JD in a two-part series on advocacy and legal issues and services across the Life Span. Talking points of the segments will include Education Rights and COVID Impact, Reducing Barriers to Employment for Individuals with Disabilities, and Other Legal/Advocacy Consideration Through the Life Span. These will include introductory discussions for parents and caregivers to consider such as early intervention, education planning, the transition to adulthood/aging (independent living, employment, transportation, financial planning). Whether a person in your life is newly diagnosed or an adult, Isleen shares information for consideration across the Life Span.Isleen Gimenez Morales is an attorney by training, advocate at heart – a disabled veteran and mother to four children with special needs. She moved to Kansas City just 7 years ago to access a coordinated care clinic for one of her children who has medical complexities. Isleen understands both personally and professionally how challenging it can be to navigate resources for individuals with disabilities and the caregivers who serve them. Isleen has 14 years’ experience in the nonprofit sector reducing barriers to employment for employees with disabilities. She recently served as the Director of SpecialCare at HighPointe Financial Group where she helped individuals with disabilities and their caregivers develop financial special needs planning strategies and as the Assistant Director for Emma’s Place for Exceptional Children – once the only therapeutic childcare facility in Overland Park that served students K-12 throughout the KC metro. Isleen founded Advocate at Heart (www.advocateatheart.com) to empower individuals with disabilities and their caregivers through education, strategic person-centered, strengths-based planning, and plan implementation in partnership with an extensive community-based resource network that Isleen has painstakingly identified and vetted herself with the help of many other special needs families in the community. Isleen also serves on the board of directors for SOAR (www.soarspecialneeds.org), a nonprofit dedicated to helping the disabled community answer the questions of: will my special needs loved one be able to provide for himself/herself? What will happen to my loved one with special needs when I am gone? and Who will take care of me (the caregiver)? She currently is a trainee under Echo Autism (www.echoautism.org), expanding her commitment to better meet the needs of families/ caregivers particularly in the Autism community, and is a Leadership in Education for Neurodevelopmental Disabilities (LEND) Program graduate from Kansas University Medical Center’s Center for Childhood Health and Development (CCHD) program. Isleen graduated with a double bachelor of sciences major with honors in both Japanese and Political Science as well as a Juris Doctorate from the University of Iowa. When not assisting individuals with disabilities and their families, Isleen is employed as an attorney at UnitedLex where she assists corporate counsel as part of the company's legal team. She is conversationally fluent in Japanese and in Spanish. Isleen loves to cook and bake. She also enjoys master's swimming and Latin dancing in her spare time.

Join Dr. Holmes as she interviews Isleen Giminez Morales, JD in a two-part series on advocacy and legal issues and services across the Life Span. Talking points of the segments will include Education Rights and COVID Impact, Reducing Barriers to Employment for Individuals with Disabilities, and Other Legal/Advocacy Consideration Through the Life Span. These will include introductory discussions for parents and caregivers to consider such as early intervention, education planning, the transition to adulthood/aging (independent living, employment, transportation, financial planning). Whether a person in your life is newly diagnosed or an adult, Isleen shares information for consideration across the Life Span.Isleen Gimenez Morales is an attorney by training, advocate at heart – a disabled veteran and mother to four children with special needs. She moved to Kansas City just 7 years ago to access a coordinated care clinic for one of her children who has medical complexities. Isleen understands both personally and professionally how challenging it can be to navigate resources for individuals with disabilities and the caregivers who serve them. Isleen has 14 years’ experience in the nonprofit sector reducing barriers to employment for employees with disabilities. She recently served as the Director of SpecialCare at HighPointe Financial Group where she helped individuals with disabilities and their caregivers develop financial special needs planning strategies and as the Assistant Director for Emma’s Place for Exceptional Children – once the only therapeutic childcare facility in Overland Park that served students K-12 throughout the KC metro. Isleen founded Advocate at Heart (www.advocateatheart.com) to empower individuals with disabilities and their caregivers through education, strategic person-centered, strengths-based planning, and plan implementation in partnership with an extensive community-based resource network that Isleen has painstakingly identified and vetted herself with the help of many other special needs families in the community. Isleen also serves on the board of directors for SOAR (www.soarspecialneeds.org), a nonprofit dedicated to helping the disabled community answer the questions of: will my special needs loved one be able to provide for himself/herself? What will happen to my loved one with special needs when I am gone? and Who will take care of me (the caregiver)? She currently is a trainee under Echo Autism (www.echoautism.org), expanding her commitment to better meet the needs of families/ caregivers particularly in the Autism community, and is a Leadership in Education for Neurodevelopmental Disabilities (LEND) Program graduate from Kansas University Medical Center’s Center for Childhood Health and Development (CCHD) program. Isleen graduated with a double bachelor of sciences major with honors in both Japanese and Political Science as well as a Juris Doctorate from the University of Iowa. When not assisting individuals with disabilities and their families, Isleen is employed as an attorney at UnitedLex where she assists corporate counsel as part of the company's legal team. She is conversationally fluent in Japanese and in Spanish. Isleen loves to cook and bake. She also enjoys master's swimming and Latin dancing in her spare time.

In this episode, we flip the script a bit as we get a patient perspective for COVID19 as we welcome Anil to the show.  Anil was diagnosed with COVID19 in a small local hospital.  During the course of his hospital stay, his oxygen decreased as his heart rate and work of breathing increased.  The difficult decision was made to intubate him and transfer him to a high level of care.  Anil talks candidly about having an hour to "get his affairs in order" before he was intubated.  After his transfer, he was at Kansas University Medical Center for several weeks and he discusses his spontaneous breathing checks, zoom calls with his family, and rehabilitation.  Sadly for Anil, the virus has continued to cause him issues as he's been rehospitalized several times since the initial diagnosis and is now on several inhalers and oral steroids to breath.  This is a continuing struggle, as the day before our interview and a few days after our interview, he's been hospitalized again.  We didn't do a story you may have missed, because we wanted the focus of this episode to be on Anil and his story.  

JFK sits down with rapper Mickey Factz & neuroscientist/rapper Micah Brown to talk about mapping the brain and culture as a result. Mickey Factz, is a world renowned freestyler and American hip hop recording artist from the Bronx borough of New York City. His Discography is Albums 2016: The Achievement 2018: The New Museum 2018: I Said Yo Mixtapes 2006: In Search Of N*E*R*D 2007: Flashback Vol.1: Back to the Future 2007: Heaven's Fallout 2008: The Leak Vol.1: The Understanding 2008: The Leak Vol.2: The Inspiration 2010: thedarkphoenix#ALPHA 2010: I'm Better Than You 2011: Heaven's Fallout: 4th Anniversary Re-Release 2011: Love.Lust.Lost 2012: Mickey MauSe 2012: #Y 2012: #Ynot 2014: 740 Park Ave 2014: Love.Lust.Lost.II 2015: Y3 Micah Brown is a native if London is the General Partner at Centiment Capital, an NYC based VC Fund. Centiment Capital is the only Venture Capital firm in the US to focus on investing in technical founders of color working on Deep Tech and Neuroscience business problems, leveraging its unique IP Syndication Financing Model, Valuation Artifical Intelligence tools and Mezzanine Financing Models to fund pre-seed and seed stage startups. Micah is also the CEO and Founder of Centiment, a Neurodata AI Company, and Filmfundr, which is AI driven Film Technology, which was acquired by Battery Park Entertainment in 2018. Micah has worked as a senior level technology consultant and manager within the insurance industry for Aon as well as in commercial, retail and investment banking at Barclays. Micah has also worked within media technology for Viacom and NBC and has a culminate 14 years of technology experience as an Engineer and C Level Executive. Micah pioneered Neurodata driven Artificial Intelligence, and the field he created, Neurosentiment, in as early as 2014, writing groundbreaking white papers and ultimately being the first person of color to commission a Neuroscience AI study with the Kansas University Medical Center and to gain investment from Sprint in American History. In 2019, Micah made history again by being the first POC in US history to win various awards at MIT for his work. Micah grew up in Catford, South London, raised by great parents despite many economic hardships. Micah received National Honors from Uxbridge College, and gained the opportunity due to his academic and work achievements to move to the US in 2013. Micah has done a great deal of charitable work also, working on the CCNY Codes initiative which saw 300 young people of color from CCNY gain roles at Amazon, Facebook and Google, for the first time in the colleges 113 year history.

Katie Siengsukon is a Physical Therapist and researcher at the Kansas University Medical Center where she is the director of the Sleep, Health, and Wellness Laboratory. Her line of research seeks to understand how sleep impacts function, learning, and overall health particularly with aging and in those with neurological conditions. She possesses a clinical background in outpatient physical therapy treating individuals with musculoskeletal and neurologic injury. Her passion as a PT is helping people sleep better. Find her on twitter @KatieSleepPT Find her bio here

Katie Siengsukon is a Physical Therapist and researcher at the Kansas University Medical Center where she is the director of the Sleep, Health, and Wellness Laboratory. Her line of research seeks to understand how sleep impacts function, learning, and overall health particularly with aging and in those with neurological conditions. She possesses a clinical background in outpatient physical therapy treating individuals with musculoskeletal and neurologic injury. Her passion as a PT is helping people sleep better. On twitter @KatieSleepPT Find her bio here

Jane Ferguson:  Hello, everyone. Welcome to Episode 23 of Getting Personal, Omics of the Heart, the podcast from Circulation: Genomic and Precision Medicine. It's December 2018. I'm Jane Ferguson. So let's get started.                              This month I talked to Dr. Merlin Butler from Kansas University Medical Center about an interesting clinical case he described recently in the Journal of Pediatric Genetics, concerning cardiac presentations in a case of classic Ehlers-Danlos syndrome with COL5A1 mutations.                              Keep listening for that interview, but first, let's talk about the papers in this month's issue of the Journal.                              Our first paper, entitled "Effects of Genetic Variance Associated With Familial Hypercholesterolemia on LDL Cholesterol Levels and Cardiovascular Outcomes in the Million Veteran Program." Comes from Yan Sun, Peter Wilson and co-authors on behalf of the V.A. Million Veterans Program. They were interested in the relatively between variants in LDLR, APOB and PCSK9, and LDL cholesterol in the general population. Low-frequency variants in these genes have been identified to underlie the greatly elevated LDL cholesterol seen in cases of familial hypercholesterolemia, but the effects of the population level are unknown.                              Using data from the Million Veterans Program, the team analyzed the associations between putatively pathogenic variants and the maximum recorded LDL cholesterol level, as measured repeatedly over a 15-year period, in over 330,000 participants. They restricted analysis to variants that were present in at least 30 people and found that eight of the 16 variants tested were associated with significantly higher LDL cholesterol. Through phenome-wide association analysis, they found that carriers had a higher likelihood of a diagnosis of hypercholesterolemia or coronary heart disease, but not of other diagnoses. Even though individuals carrying risk variants generally reduce their LDL cholesterol through statin treatment, they still had residual risk, suggesting that even earlier initiation of treatment may be required in individuals with genetic risk of high HDL.                              Continuing the theme, the next paper comes from Laurens Reeskamp, Merel Hartgers, Kees Hovingh and colleagues from the University of Amsterdam, and is entitled, "A Deep Intronic Variant in LDLR in Familial Hypercholesterolemia: Time to Widen the Scope?" This team had encountered a family with familial hypercholesterolemia, who did not carry a coding mutation in LDLR, APOB or PCSK9, and they wanted to figure out what was causing the elevated LDL cholesterol in this family. They conducted whole-genome sequencing in nine family members, five affected and four unaffected. They found a variant in an intron in LDLR, which resulted in an insertion of 97 nucleotides, leading to a frame shift in premature stop codon in exon 15 of LDLR. They confirmed the disease segregation in a second family, and found a frequency of over 0.2% in additional FH cases without a confirmed mutation.  This study highlights the need to consider more than just exons when looking for causal variants, particularly in families where no coding mutations are identified.                              Next up, from Kathryn Siewert and Ben Voight from University of Pennsylvania, a paper reporting that "Bivariate Genome-Wide Association Scan Identified 6 Novel Loci Associated With Lipid Levels and Coronary Artery Disease." This paper started with a premise that, because heritable plasma lipids are genetically linked to coronary artery disease, we would have greater power to detect variants contributing to both traits by conducting joint GWAS analysis, rather than independent analyses for lipids or coronary disease, as has been done traditionally. Using data from over 500,000 individuals for CAD and over 180,000 individuals from the Global Lipid Genetics Consortium, they conducted a bivariate GWAS and identified six previously unreported loci that associated with CAD and either triglycerides, LDL cholesterol or total cholesterol. Many of these loci also had signals for effects on gene expression of genes in the region, suggesting that these novel loci may affect lipid levels and CAD risk through modulation of gene expression. Interestingly, for some of the newly-identified loci, there were multiple potential regulatory targets, suggesting that these loci may affect lipids and CAD through separate mechanisms. Overall, for closely-linked traits such as lipids and CAD, this joint GWAS approach gives additional power to detect novel variants.                              The next article comes from Terry Solomon, John-Bjarne Hansen and colleagues from University of California-San Diego and the Arctic University of Norway. Their paper concerns the "Identification of Common and Rare Genetic Variation Associated With Plasma Protein Levels Using Whole-Exome Sequencing and Mass Spectrometry." They were interested in identifying genetic variants that associate with plasma protein levels, both to understand genetic regulation and to identify potential sources of bias, where a genetic variant affects the assay used to quantify the protein, without necessarily altering biological components of the protein. Using data from 165 participants of the Tromsø Study, they quantified 664 proteins in plasma by tandem mass tag mass spectrometry and genotypes by whole-exome sequencing. They identified 109 proteins or peptides associated with genotype, and of these identified 49 that appeared to be technical artifacts based on genotype data.  Of the rest, many of the genetic variants affected protein level by modulation of RNA, but some appeared to directly affect protein metabolism. Their method of quantifying multiple peptides from each protein and sequencing exons allowed them to identify spurious associations that would often be missed, and highlights the large number of artifacts that could be present in protein quantitative trait locus studies. At the same time, they show that over half of the pQTLs are real, with genetic variants affecting circulating proteins through diverse mechanisms.                              Our last of the full-length original research articles also applied proteomics. "Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy" comes from Caroline Coats, Perry Elliott and coauthors from University College, London. They obtained myocardial samples from 11 patients with hypertrophic cardiomyopathy and measured over 1500 proteins using label-free proteomic analysis. They compared protein expression to six control samples from healthy hearts. They identified 151 proteins that were differentially expressed in HCM hearts, compared with control, and they validated a subset of these using an additional 65 myocardial samples from healthy and diseased subjects. Of eight validated differentially expressed proteins, they represented pathways in metabolism, muscle contraction, calcium regulation and oxidative stress. Of particular interest, they highlighted lumican as a novel disease protein, and showed the potential of proteomics to identify mechanisms underlying HCM.                              We have two research letters this month, the first from Hisato Suzuki, Kenjiro Kosaki and coauthors from Keio University School of Medicine at Tokyo. It's titled, "Genomic Comparison With Supercentenarians Identifies RNF213 as a Risk Gene for Pulmonary Arterial Hypertension." In this letter, they were interested in identifying genetic variants underlying pulmonary arterial hypertension. They hypothesized that individuals with extremely long lifespan would be less likely to carry potentially pathogenic variants. They performed whole-exome sequencing in 76 individuals with PAH and compared them to 79 supercentenarians who had lived for over 110 years. They report variants in RNF213 and TMEM8A that were present in PAH but not in the controls, suggesting these genes may be important in the pathophysiology of PAH.                              The second research letter comes from Tessa Barrett, Jeffrey Berger and colleagues from New York University School of Medicine, and is entitled, "Whole-Blood Transcriptome Profiling Identifies Women With Myocardial Infarction With Nonobstructive Coronary Artery Disease: Findings From the American Heart Association Go Red for Women Strategically Focused Research Network." Most of the 750,000 acute MIs occurring in the U.S. each year are caused by obstructive coronary artery disease, but around 15% of the acute MIs occur in individuals whose arteries have less than 50% stenosis and are defined as unobstructed. These individuals are more likely to be female and of higher morbidity and mortality. In this AHSAFRM-funded project, the team sequenced whole-blood RNA from 32 women who presented with an MI with or without CAD, or controls. They report several thousand transcripts differing between groups on conducted pathway analysis, which highlighted several pathways, most notably estrogen signaling. This suggests that estrogen may be a novel component in MIs occurring in the absence of obstructive disease.                              We also have two clinical letters this month. The first, "Desmoplakin Variant-Associated Arrhythmogenic Cardiomyopathy Presenting as Acute Myocarditis," is brought to us by Kaitlyn Reichl, Chetan Shenoy and colleagues from University of Minnesota Medical School. They report a case of a 24-year-old man presenting with acute myocarditis, who was found to have a pathogenic variant in desmoplakin underlying arrhythmogenic cardiomyopathy, also present in his father and one brother. This case highlights myocarditis as a possible initial presentation of arrhythmogenic cardiomyopathy, which requires cardiac MRI and genetic testing for full evaluation.                              The second clinical letter comes from Judith Verhagen, Marja Wessels and co-authors from University Medical Center, Rotterdam, and is entitled, "Homozygous Truncating Variant in PKP2 Causes Hypoplastic Left Heart Syndrome." They report on a family with consanguineous parents, where two children were affected with left ventricular hypoplasia, leading to intrauterine death in one child and death at day 19 of life in a second child. Sequencing identified a variant in PKP2, which encodes plakophilin 2. Both parents were heterozygous for the mutation, and their affected children were homozygous for the mutation. This mutation resulted in disorganization of the sarcomere and affected localization of other proteins affecting gap junctions. The case highlights PKP2 variants as causal in hypoplastic left heart syndrome.                              Dr. Merlin Butler is a professor at Kansas University Medical Center and Director of their Division of Research and Genetics. Dr. Butler joined me to discuss an interesting case of Ehlers-Danlos Syndrome in a father and son, with heart failure in the father. This case is in press in the Journal of Pediatric Genetics, and the prepublication version is available online, published on the 13th of October 2018. We'll tweet out a link to that paper, if you're interested in viewing the full case, but here's Dr. Butler, who joined me to discuss it now. Dr. Butler:          ... I'm a clinical geneticist here at University of Kansas Medical Center, and I see both adult and pediatric patients, but one of the more common reasons for referral to my adult side clinical genetic services is connective tissue disorders. And that's how we were involved with this particular family, a son and father, that led to my interest in looking at the question about genetics of cardiac transplantation of those patients that present for cardiology services because of heart failure and worked up and ultimately end up as a candidate for transplantation.                              And that transpired in this particular family, which the patient was a 13-year-old boy who was referred into the clinic because of connective tissue disorder. Actually the primary care wanted to rule out Ehlers-Danlos Syndrome. And so we evaluated the 13-year-old boy in the clinic setting, and then we ordered comprehensive connective tissue and next-generation DNA sequencing panel, and lo and behold, he had a mutation of the classical gene that causes classic Ehlers-Danlos, the collagen 5A1 gene. The gene variant was classified as unknown clinical significance, which is often the case as we know with this technology, next-generation sequencing. Regardless of the condition we're looking at, we find about 10% of time, the panel of tests, the panel of genes that come back that are tested. 10% of the time we find no variants, no spelling errors, no mutations. 10% of the time the results come back from the commercial laboratory ... these are clinic patients, so it's done in commercially-approved laboratories, clinically-approved laboratories ... and we find that about 10% is pathogenic, which means it's disease-causing. The gene variant or mutation has been reported before. There is information in the literature that we know that it causes disease, Ehlers-Danlos, whatever type.                              About 80% of the time, the results come back as unknown clinical significance, and this is related to connective tissue. You probably order a test in cardiology or any other service and you'll find the same area. Most of the variants come back as unknown. What is meant by that is they haven't been reported previously in the literature, and therefore we don't know ... They may be disease-causing, that particular change, but we don't know that. We as geneticists, we have to then figure out whether that gene variant is a mutation or background noise. So we go through a process by where we try to characterize that particular gene finding to see whether it could be causative in that particular patient we see, or if it looks like it's probably tolerated and is just background noise, and it has really probably no apparent phenotypic change resulting from that particular gene variant.                              So this particular gene variant that we found, the collagen 5A1, did meet the criteria. We looked for computer programs and silica prediction to see if it was tolerated or damaging. We looked at how common that gene variant is seen in the general population, looking at exact various types of genome databases at the laboratories used to search for that variant in the population that's been serviced by genetic services, to see how rare it is or how common it is. We also check to see if it's a missense change, missense variant that is, one amino acid got switched for a different amino acid. There are five classes of amino acids, so if they stay within the same class, that change one amino acid to the next probably doesn't have much meaning, but if it changes to an entirely different class, like positive to negative, hydrophilic to hydrophobic, that could make a big change at the protein translation level, and therefore impact on protein development and function.                              And then we looked to see if it's conserved in evolution. The laboratories that we use, they look at approximately 80 different animals, mammals, vertebrates, primates, non-mammal vertebrates, to see if that particular spelling change is conserved throughout evolution. If it is, if C is always that position 205 in the coding sequence of that gene throughout evolution, that means you need to have C at that position, not A, G or T, because that would be conserved and impact that we don't want to change that, because it's conserved through evolution.                              So those kind of criteria, how common it is in the population, how conserved it is, what the amino acid change might be and what the computer programs predict that change might relate to the function of the protein. So we used those criteria, found this gene variant, although it hadn't been reported before ... well, it hasn't been characterized as pathogenic. In this particular family, 13-year-old son and 55-year-old father, they both had the classical features of classic Ehlers-Danlos, so that gene variant, we know at this point is informative. Dr. Ferguson:    That's a really helpful introduction to how you go about looking at variants and screening them and picking the ones of most importance. So you had this 13-year-old patient who came in and then you tested the patient, and then did you also test both parents? Other family members? Dr. Butler:          Well, the mother was no longer in the loop, so the primary care, the pediatrician, referred this 13-year-old boy because of joint laxity. He had experienced multiple spontaneous knee dislocations, beginning around nine years of age. He was 13 when I saw him in clinic. He had a history of knee pain, generalized joint hypermobility, loose skin, excessive bruising and poor scarring. And he had that history coming in, and we certainly could identify those findings on this patient. In fact, we reported this patient in the literature. The title of the paper is "Classic Ehlers-Danlos Syndrome in a Son and Father with a Heart Transplant Performed in the Father," published in Journal of Pediatric Genetics, but during a genetics clinic visit, we assessed a hypermobility Beighton scale, that we used to determine the degree of hypermobility, hyperflexibility, and we recorded a score of eight out of nine. Nine is the maximum number. And what we use as kind of a cut-off, this score is five or more, five out of nine or more, then that would indicate that probably there is some kind of joint issues, connective tissue disorder in the way.                              He had no heart murmur detected, normal rate and rhythm, but a previous echocardiogram showing he had no valvular problems but he had aortic root dilation. He also had skin marbling, atrophic scars, particularly on the lower leg, and increased pigment secondary to easy bruising. He had asymmetry of the anterior body wall, pretty classical findings that we recognize in Ehlers-Danlos. Dr. Ferguson:    So the reason we're talking to you about this is actually less related to the son, right? And then related to what you found in the father. Dr. Butler:          The father, right. So the father was 55 years old when we saw him. So we did testing on the son, based on his examinations, and then we obtained DNA and we found out, had the sequencing. We found he had a gene variant of the collagen 5A1 gene. And the collagen 5A1 codes for collagen, low fibrils protein changes, and that's a classical finding we see in Ehlers-Danlos. So we then, on follow-up, we looked more closely at the father, based on what we found in the child, and the father is 55 years of age and he exhibited similar clinical features seen in his son, including stretchable, thin skin, poor scarring, hypermobile joints, with pain and easy bruising. He had a Beighton score of six out of nine, but due to multiple knee surgeries, we were really not able to able to assess his knee findings.                              And he had strabismus repair when he was like 12 years of age. He had surgery on his right knee due to frequent dislocations, and had bilateral foot surgeries due to flat feet, pes planus. He had a stroke at 37 years of age, but without hypertension. At 43 years of age he underwent a heart transplant because of heart failure with no known cause, such as infections or anatomical defects or metabolic problems seen. And at 54 years of age he had fusion of the lower vertebrae, correct complications, nerve compression, impacting ambulation. So he had multiple, multiple problems, and we did DNA testing on him. He also had the same gene variant of the collagen 5A1 gene, which causes classic Ehlers-Danlos Syndrome. Dr. Ferguson:    Yeah, so he essentially had been undiagnosed his entire life, I guess. Dr. Butler:          In his entire life, he just kind of lived with it. Obviously no one really picked it up because he had multiple, multiple orthopedic surgeries. Of course he had the cardiac transplant because of a very large heart size. They didn't really find out what had taken place with that. They didn't find any reason why he had heart failure. So, because of this connective tissue issue, I began to think more closely about this. Could somehow his cardiac transplantation due to no determined reason why he had heart failure, could that somehow be related to a connective tissue problem, such as classic Ehlers-Danlos?                              And classic Ehlers-Danlos is fairly common, about one in 20,000 people. As far as our concern in the field of genetics, one in 20,000 is common, because we see rare diseases. So one in 20,000 is common. There's like six different categories of Ehlers-Danlos in classic and hypermobile form, vascular form, but he had the clinical findings, he and his son, and he had mutation of a gene that causes classic Ehlers-Danlos.                              So the thrust of this communication is, could it be that there may be a group of individuals that are on a heart transplantation service, waiting to be transplanted, that might have a connective tissue disorder, such as Ehlers-Danlos or one of the other connective tissue disorders, that could be an issue and a causation of their cardiac issues? We know that there are around 70 genes being recognized that cause connective tissue, and these numbers increase all the time as we learn more about genetics and the capabilities of testing. There are over 130 recognized genes that are thought to play a role in hereditary cardiomyopathies and there are now thought to be over 230 genes that are commercially available in a comprehensive cardiovascular next-generation DNA panels, and several of those genes are collagen genes.                              So we know there are hundreds of genes that play a role with cardiac health, I guess. Disturbance of those genes, several of those could be connective tissue. Obviously there's others involved, too ... myopathies and conduction issues. But the question I would have, the focus is, could there be a group that would have a connective tissue? And why is that important? Well, not only do they have issues when it comes to these multiple surgical concerns, but they may have, obviously, concerns that might be related to complications of surgery. We know that connective tissue disorders, they have poor wound healing, scarring and other tissue involvement such as vascular anomalies, aneurysms. So they become ... whether it's for cardiac procedures or whether it's orthopedic, whatever ... they become poor candidates for surgical intervention, for surgical operation procedures, because of the complications of surgery. Connective tissue, poor wound healing, scarring.                              And because connective tissue is involved in not only the skin, but involves internal organs such as the vessels, where you're concerned about aneurysms and vascular anomalies, that could be playing a role. So there may be more complications related to the surgical procedures than your typical patient who undergoes heart transplantation.                              So I think that would be important to know, so I would encourage, for the cardiology services, for patients that are on these transplant care and services, to consider a comprehensive genetic DNA analysis to look at connective tissues, as well as other causations of cardiac disease. As I mentioned, there's over 200 different genes been recognized now on comprehensive DNA testing panels related to cardiac and connective tissue problems.                              So, I would encourage that patients that are on the transplant list, they should undergo a next-generation detailed comprehensive connective and cardiovascular panel ... they're certainly available in several laboratory settings ... that might help lead to not only the diagnosis of the cardiac issues, but might help in medical management and monitoring and the surveillance, as well as the surgical interventions and care following the surgical procedures might be taking place.                              Frequently have an arterial wall might be a little fragile and obviously clamping during surgical procedures for an extended period of time might cause some trauma, even to a normal artery, let alone an artery that might be disorganized because of connective tissue problem. Dr. Ferguson:    Yeah. Dr. Butler:          So those complications might occur as well, too, during the procedure or following the procedure. Even there may not be any aneurysms going in, there might be a weakness of the arterial wall at the clamp site that could lead to an aneurysm following the procedure, so it needs to be monitored.                              So I'm just bringing these to the medical attention that may or may not be out there, but I want to bring this to ... You know, there have been over 90,000 heart transplants been done since 1983, at least that many, and there's 23 million people worldwide that are affected with congestive heart failure, and that's about 7.5 million people in North America. Dr. Ferguson:    Yeah. Dr. Butler:          So it's out there. Some of these genetic conditions are rare, but collectively they're common. Ehlers-Danlos, one in 20,000, is probably considered rare, but yet it still is not rare to the person that has it. Dr. Ferguson:    Right, right, and maybe enriched in these patient populations. So is this something you think that could be sort of found with more careful physical exams, or do you think that [crosstalk] genomic sequencing is sort of the best way to get at this? Dr. Butler:          Well, I think that Beighton scale we just mentioned, the hypermobility scale, just to see if there's, you know, if it's pretty common. Most adults can't put their palms on the floor when they're standing up. Dr. Ferguson:    I certainly can't. Dr. Butler:          That is usually not gonna happen for multiple reasons. But maybe some of the cardiologists are, but those that aren't, maybe they should consider, just check for hyperflexibility in their adult patient. [crosstalk] Dr. Ferguson:    Yeah, that seems like an easy [crosstalk] click-and-check, right? Dr. Butler:          Right. There being loose skins, poor scarring. You can ask the patient, obviously. Easy bruisability and poor scars, and it's pretty obvious in these conditions. I mean, on a physical exam it jumps out at you, particularly the multiple scars and bruising on the lower extremities with the pigmented because of iron deposits. You'll see that pretty clear in the scarring issues.                              And they'll tell you, too. I mean, the patients, they know. "Oh, yeah. I'm very hyperflexible." So you just ask the question and the patients will tell you. They say yes, and then it might need further testing physically; that is, actually do the exam and see if they have, on this Beighton scale, what the hyperflexibility score looks like. And if it is positive ... what we consider positive is five and above, five out of nine ... then those would candidates for a comprehensive DNA testing, whether it's related to cardiomyopathies, but I think connective tissue collection genes. Like I say, there's roughly 70 of these genes out there now that we test for in the commercial clinical laboratory setting. That should be monitored, as well as adding other genes if need be. So I'd encourage that.                              Physical examination number one. If it's positive, then check into a DNA panel for these types of disorders. It could help long-term for the care and outcome of the patient. Dr. Ferguson:    Yeah. I do think that's really important from the patient perspective and then, if more of these cases start being reported, I think it's very interesting also from the research perspective to find out what are the mechanisms that are potentially linking these mutations to cardiac disorders which have- [crosstalk] Dr. Butler:          That's true, and also realize that a lot of these patients have hypotension, and that can lead to some complications before, during and after surgical intervention, too. Dr. Ferguson:    Yeah. Dr. Butler:          So that's important to realize. Dr. Ferguson:    Very important. Yeah. So thank you for telling us about this interesting case and for raising this. I think it's an important issue and I'm sure a lot of the cardiologists and clinicians listening will start to look out for connective tissue disorders in their own patients. Dr. Butler:          I think, first thing is just ask questions. Are you hyperflexible? And they'll tell you. It's something that is very obvious to the patient. It will be obvious to the physician once he or she puts their hands on the patient, examine the patient, they realize, "Oh, this patient really is quite hyperflexible, digits and arms and knees and elbows," et cetera, et cetera. But, just ask the question, are they hyperflexible? If they say no, then the connective tissue is lower. It still could be. There could still be some aneurysms, those kind of things going on because there's, like I say, there's 70 genes, and there's six types of Ehlers-Danlos, so there's many other conditions out there that kind of look like an Ehlers-Danlos, but they're not. They may have another gene involving protein that's related to connective tissue, but not in the Ehlers-Danlos group of disorders or genes. Still could play a role. Could be similar. They may [inaudible] aneurysms, and that's important to know before they get into the procedures, too. Dr. Ferguson:    Yeah, really important, really interesting. Thank you so much for joining us.                              Thanks, everyone, for listening. And I wish you all the best for the holiday season, and a very happy new year. We're looking forward to bringing you lots more in 2019.                              This podcast was brought to you by Circulation: Genomic and Precision Medicine, and the American Heart Association Council on Genomic and Precision Medicine. This program is copyright American Heart Association, 2018.  

Ruth Leyse-Wallace, PhD was in one of the first dietetic internship programs that became Registered Dietitians in 1971 continuing the credential for 44 years. Her studies in dietetics began at Oklahoma State University and continued through the University of California at Davis earning a BS degree under advisor Frances Zeman, PhD. She obtained an MS degree and completed an internship at the Kansas University Medical Center under the internship Director Norge Jerome, PhD. Her career began at Osawatomie State Hospital in Kansas, continued at The Menninger Foundation in Topkea, Kansas, Sharp Mesa Vista Hospital in San Diego, and HPA Willow Park Hospital in Plano Texas. She returned to graduate school and earned a PhD degree in 1998 at the University of Arizona in Tucson, under the guidance of Mary Ann Kight, PhD, RD. Dr Leyse-Wallace has served as adjunct faculty at Pima County Community College in Tucson, AZ and Mesa Community College in San Diego, CA. She has published three books: The Metaparadigm of Clinical Dietetics: Derivation and Application, Linking Nutrition To Mental Health, and Nutrition and Mental Health. She served five years as the Mental Health Resource Professional for the Behavioral Health Nutrition Dietetic Practice Group of the Academy of Nutrition and Dietetics.

Get high-powered, productive, and crushing your business goals! My fabulous guest and I dive deep into ways of breaking down the data of productivity, with tips on goal setting, book writing, podcasting, and so much more! A few exciting highlights include:- Podcast Movement is almost here! - Should you wait until your brand is 100% on point before launching? - What is one GREAT question to ask to make important decisions? (Clarity vs. Confusion) - How to balance the 'fear of disappointing others' - Gain some incredible tips on productivity broken down by day, week, month and quarters! - Learn some great tips on being productive and building your brand! - Find out some of Amanda's favorite tools to use online! - Gain some tips on setting goals and working on them! - Get some advice about considering focusing on one gender, all genders and/or everyone?! - Hear about Megan Minns and Asanahq and why $97 just isn’t enough! - Should you 'kill' your news feed? (Hint: yes) - Practice a 12 week year! What? Yes!!   Take Action Now! Free TRAINING on Hitting Amazon Best Seller! Free COMMUNITY to Collab with as you Write Your Best Seller! The Best IMPLEMENTATION PROGRAM to Hit Amazon Best Seller! Email me for info on my new INNER CIRCLE (Laura@CopyThatPops.com) Guest: Amanda has worked with over 10,000 individuals stretching to all corners of the country and internationally shifting mindset and changing behaviors way of sales training and leadership development programs, primarily in call centers. Clients she has worked with are ATT, Intel, JP Morgan, Weight Watchers, Goodcity Chicago, Kansas University Medical Center. Her previous experience in retail management and human resource strategies at Fortune 500 companies is relevant to her current work. She is best described as an individual who lives in a world of what’s possible. In January 2015, Amanda founded and launched the She Did It Her Way podcast, a podcast dedicated to featuring savvy, female business entrepreneurs from across the globe. Through weekly podcasts, monthly memberships and an annual event, She Did It Her Way is on a mission to help create more female entrepreneurs by successfully transitioning from Corporate America to full-time entrepreneur, through weekly podcasts, monthly memberships and in-person events. She Did It Her Way has consistently been named as a top-rated resource by Forbes.com, Inc.com, Entrepreneur, Huffington Post and others. --------- Most days you can find Amanda working from her apartment in Chicago, waking up early to catch the sunrise, smiling at life and hanging out with her favorite human being, her husband. She is mostly known for her enthusiasm towards life and her love for early mornings watching sunrises, journaling while sipping her Nespresso coffee on her building’s rooftop that overlooks the city of Chicago. People often refer to her as the energizer bunny and someone who is high on life. She loves serving the world by connecting women for good and fostering intentional and authentic relationships. The things she is most passionate about in life are raw conversations that get to the heart and soul of another human being; everything in life is a choice and seeking growth. She works with women who have a drive and desire to run their own business, be their own boss and be in the driver seat of their life. She is lucky to teach them how to successfully launch their business, transition out of Corporate America, and create freedom for their life. As an educator she has been featured in Forbes, Inc.com, Entrepreneur.com, Huffington Post, Tech Stars and other publications for providing a platform where women can learn, connect, and grow. When she is not busy working you can catch her: Organizing her home Reading self-help books Watching a Real Housewives show or two Working out at the gym Testing out a new recipe, sipping wine, listening to Van Morrison Great Quotes: “When you take action, that actually breeds an outcome.”– Amanda Boleyn “Owning your own business is a very personal journey.” – Amanda Boleyn “If we don’t have a plan for what we’re doing with money, we don’t have a reason to defend it.” – Amanda Boleyn “Track your time and add them up at the end of the week so you can track your time.”– Amanda Boleyn “If you could remove the mindset block of women specifically, imagine how much content could flourish.” – Amanda Boleyn “What are the things in your life that are clouding your vision?” – Amanda Boleyn “Ask yourself, ‘Does this provide more clarity or more confusion in my life?’” – Amanda Boleyn “We have a fear of disappointing people.” – Amanda Boleyn Links to Things Mentioned in This Podcast Episode: Podcast Movement 2018 She did it her Way Podcast Free Facebook group to help you with your book! Toggl Your One Word Quick Tip! Read More: Shownotes for 134: Productivity Hacks and Hitting Big Goals with She Did It Her Way Leader Amanda Boleyn

With special guest Connie Chappelle, RN, MN, CLNC, risk management coordinator for Kansas University Medical Center in Kansas City, and Allen Frady, RN, BSN, CCDS, CCS, CDI Education Specialist at HCPro and the Association of Clinical Documentation Improvement Specialists (ACDIS).

In Episode 34 of the Alliance Podcast, Mary Dickerson and John Godfrey of the University of Houston and Kansas University Medical Center weigh in on the challenges of educating the next generation of cyber security professionals. What is currently being done? What are the barriers preventing more students from entering the field? What are the biggest challenges Universities face with regards to Information Security? Join Host AJ Eads, Director of Communications for the Alliance along with two incredible guests to learn more about this fascinating topic and how two of our executive members are making an incredible difference.

Learn About the Science and Clinical Usefullness of I.V. Vitamin C as a Treatment for Cancer in Conjunction with Traditional Therapy and the Synergistic Benefit of Adding the Ketogenic Diet and Hyperbaric Oxygen Modalities Kirk Hamilton interviews Jeanne Drisko, MD, Director of the Integrative Medicine Department at Kansas University Medical Center and the Riordan Endowed Professor of Orthomolecular Medicine on her current research and clinical work using intravenous vitamin C, the ketogenic diet and hyperbaric oxygen therapy in conjunction with traditional oncology to treating cancer.  Dr. Drisko's work on I.V. vitamin C for cancer as well as for diabetes, infections and chronic fatigue, among other conditions, is being overseen my Mark Levine, MD at the National Institutes of Health. Dr. Drisko has been interviewed on two other occasions on I.V. vitamin C and cancer on the Staying Healthy Today Show in 2009 and 2011. (Interview Timeline - Intro: 0-2:07; I.V. Vitamin C and Cancer Treatment: 2:08-34:00; Nutritional Assessment: 34:00-37:00; Ketogenic Diet 37:15-42:10; Neurofeedback Therapy for "Chemo-Brain" 45:15-45:45) Download or Open:

Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, covering question of optimal treatment for patients with advanced NSCLC who are elderly or have a marginal performance status.

Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, covering question of optimal treatment for patients with advanced NSCLC who are elderly or have a marginal performance status.

Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing options for administering multimodality therapy for stage III NSCLC in patients who are elderly or have a marginal performance status.

Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing options for administering multimodality therapy for stage III NSCLC in patients who are elderly or have a marginal performance status.

Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing current evidence and challenges of post-operative treatments for early stage NSCLC in elderly and/or frail patients.

Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing current evidence and challenges of post-operative treatments for early stage NSCLC in elderly and/or frail patients.